2024 Update on the Treatment of Attention Deficit-Hyperactivity Disorder (27 min.)
$25.00
In this presentation, Dr. David Urion discusses medication and research updates relating to the diagnosis and treatment of Attention Deficit-Hyperactivity Disorder (ADHD). He discusses the role of bias in under- and over-diagnosis of ADHD, various screening and diagnosis tools available to providers, and medication options and effects. This presentation was recorded at the Michael J. Bresnan Child Neurology Course on September 16, 2024.
Description
David K. Urion, MD, FAAN
Director of Education, Department of Neurology, Boston Children’s Hospital
Director of Behavioral Neurology Clinics and Programs, Department of Neurology, Boston Children’s Hospital
Associate Professor of Neurology, Harvard Medical School
In this presentation, Dr. David Urion discusses medication and research updates relating to the diagnosis and treatment of Attention Deficit-Hyperactivity Disorder (ADHD). He discusses the role of bias in under- and over-diagnosis of ADHD, various screening and diagnosis tools available to providers, and medication options and effects. This presentation was recorded at the Michael J. Bresnan Child Neurology Course on September 16, 2024.
Learning Objectives: At the conclusion of this educational program, learners will be able to:
- Make logical choices about new agents being offered in the US for treatment of ADHD
- Make logical substitutions for agents currently experiencing shortages
- Monitor for side effects particular to newer agents used in the treatment of ADHD
In support of improving patient care, Boston Children’s Hospital is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician
Boston Children’s Hospital designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Nurse
Boston Children’s Hospital designates this activity for 0.5 contact hours for nurses. Nurses should only claim credit commensurate with the extent of their participation in the activity.
Disclosure Policy
Boston Children’s Hospital adheres to all ACCME Essential Areas, Standards, and Policies. It is Boston Children’s policy that those who have influenced the content of a CE activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that Boston Children’s may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.
Disclosure Statement
The following planners, speakers, and content reviewers, on behalf of themselves, have reported the following relevant financial relationships with any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on patients:
David K. Urion, MD, FAAN: None
Miya Bernson-Leung, MD, EdM: Abbott Labs – individual stock holder; Abbvie Inc – individual stock options
Additional information
| Credit Type | AMA PRA Category 1 Credits™ (MD, DO, NP, PA), Contact Hours (Nurse, Nurse Practitioner) |
|---|---|
| Duration | |
| Format | |
| Topic | |
| Expiration Date | |
| Release Date |
